Sign Out
Pregnancy: Due to the potential reproductive toxicity, the intrinsic risk of bleeding and the evidence that rivaroxaban passes the placenta, Rivaxored is contraindicated during pregnancy (see Contraindications).
Women of childbearing potential should avoid becoming pregnant during treatment with rivaroxaban.
Breast-feeding: Safety and efficacy of Rivaroxaban have not been established in breast-feeding women. Rivaxored is contraindicated during breast-feeding (see Contraindications). A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy.
Fertility: No data is available with rivaroxaban to evaluate effects on fertility.
Continue with Google